Dossier overview
3
research areas
3
references
3
handling notes
01
Mechanism of action
Historical research has associated DSIP with delta-sleep induction, modulation of neurotransmitter and hormone levels, and stress-related signalling — though across the literature the dose-response is described as U-shaped and the mechanism remains incompletely characterised.
02
Research applications
- Sleep biology research
- Stress-axis pharmacology research
- Comparative short-peptide signalling research
Evidence at a glance
What's behind this profile
3 citations · 1984–2001
- Review
- 3
Narrative or systematic reviews; no primary data.
Publication years
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 00
- 01
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Delta-sleep-inducing peptide (DSIP): a review
1984
Graf MV et al. · Neuroscience & Biobehavioural Reviews
- Model
- Comprehensive narrative review of animal and early human DSIP research
- Sample
- N/A (review)
Reviewed DSIP's U-shaped dose-response sleep effects across species and the proposed neurotransmitter and hormonal interactions.
Delta-sleep-inducing peptide (DSIP): an update
1986
Graf MV et al. · Peptides
- Model
- Updated narrative review covering animal and early clinical applications
- Sample
- N/A (review)
Updated review documenting reported DSIP effects in insomnia, pain, and withdrawal contexts from the 1980s literature.
Delta sleep-inducing peptide
2001
Pollard BJ et al. · European Journal of Anaesthesiology
- Model
- Narrative review
- Sample
- N/A (review)
Overview of DSIP's physiological properties and the state of the published evidence as of 2001.
Evidence caveats
- Most cited primary literature dates from the 1970s–2000s. Modern controlled human clinical trials are limited or absent from major databases.
- DSIP is not approved as a medicine in any jurisdiction. Mechanism and efficacy remain incompletely characterised.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Research-only inventory; not for human use.
- Maintain batch and supplier documentation.
- Limited modern protocol documentation — verify supplier-specific guidance.